← Back to Search

Marijuana for Cannabis Use

Phase 1
Waitlist Available
Research Sponsored by Shanna Babalonis, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up these outcomes will be recorded prior to and in regular intervals after drug administration for the duration of the session (approx. 9 hrs)
Awards & highlights

Study Summary

This trial will study how different strains of marijuana affect driving performance, and compare those effects to alcohol.

Eligible Conditions
  • Cannabis Use
  • Cannabis
  • Alcohol Consumption

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~these outcomes will be recorded prior to and in regular intervals after drug administration for the duration of the session (approx. 9 hrs)
This trial's timeline: 3 weeks for screening, Varies for treatment, and these outcomes will be recorded prior to and in regular intervals after drug administration for the duration of the session (approx. 9 hrs) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Simulated Driving Performance
Secondary outcome measures
Subject- and Observer-Rated Outcomes

Side effects data

From 2021 Phase 1 & 2 trial • 15 Patients • NCT03253926
40%
Gastrointestinal upset
20%
Headache
13%
Trouble sleeping
13%
Eye dryness/discomfort
7%
Anxiety/Jittery
7%
Body pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lorcaserin + Marijuana
Placebo + Marijuana

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Active Marijuana DoseExperimental Treatment1 Intervention
Participants will receive experimental/non-therapeutic dose(s) of active marijuana, under double-blind conditions
Group II: Active Alcohol DoseActive Control1 Intervention
Participants will receive experimental/non-therapeutic dose(s) of active alcohol, under double-blind conditions
Group III: Inactive Alcohol DosePlacebo Group2 Interventions
Participants will receive experimental/non-therapeutic dose(s) of inactive alcohol, under double-blind conditions
Group IV: Inactive Marijuana DosePlacebo Group2 Interventions
Participants will receive experimental/non-therapeutic dose(s) of inactive marijuana, under double-blind conditions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Marijuana
2008
Completed Phase 2
~360

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Shanna Babalonis, PhDLead Sponsor
2 Previous Clinical Trials
21 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,464 Previous Clinical Trials
2,618,559 Total Patients Enrolled
28 Trials studying Cannabis Use
6,123 Patients Enrolled for Cannabis Use

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
New York
Kentucky
How old are they?
18 - 65
What site did they apply to?
University of Kentucky
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Recent research and studies
clinicaltrials.govStudy
Marijuana Effects on Simulated Driving Performance
Shanna Babalonis, PhD 2019. "Marijuana Effects on Simulated Driving Performance". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03699540.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top